Cross Atlantic Commodities Inc. (fka CXAC)

[la izzy]

10-16-2009
Shareholder Letter and Mid Month report
Dear Shareholders:
It is with great pride that I will share the mid month revenue report with all our loyal shareholders. We are running
slightly ahead of last month, without any commercials or new online media buying as of this date. Our TV ads will
launch next week and we anticipate that the combination and increased awareness of our product will exceed the
sales goals for the month of October 2009. Our product has begun to slowly gain customer awareness and
recognition and sales will continue to grow exponentially in the next few months.
Here is a copy of the commercial for your review: http://www.crossac.com/rejuv_commercial.html
I am reminded of a famous quote from the first space shuttle:
Anyone who sits on top of the largest hydrogen-oxygen fueled system in the world; knowing they're going to light
the bottom—and doesn't get a little worried—does not fully understand the situation.
— John Young, after being asked if he was worried about making the first space shuttle flight
Yes, I am worried about our launch and the dangers that accompany a new product acceptance in these difficult
economic times but my trepidations are gone. Re-Juv by Caci is a winner and I will grow this Company into a much
larger concern over the next fiscal year.
Other corporate matters that I wish to address are as follows:
Please note that the trading of our stock remains UNAFFECTED by the DTC freeze. Our counsel met with them
and they have made this decision even though the Company and my office remain unscathed by the recent SEC
charges to individuals who consummated transactions with CXAC. DTC is a private
Company and will not lift the freeze until the SEC adjudicates their claims. We will remain current with our
financial disclosure to remove any rumor or taint the stock has suffered by the decision of DTC. It makes no impact
to the Company or our future!
Finally we are on the verge of launching our new product: SNOR-ENZ! This product was sold throughout the US
and Europe and is being revived by our Company. It will add significant
revenue to our bottom line and was the industry leader several years ago. There is nothing in the market that can
compete with the product and our commercial launch is imminent.
I have added the following information about the product history:
SNORenz® is an original and innovative entry into the anti- snoring industry. Never before has any company
introduced a liquid throat spray to prevent or quiet the noise of snoring. The medical and psychological
communities have studied the causes and symptoms of sleep deprivation for many years.
p. 305.970.7039 | f. 707.371.7039 | email: [e-mail] | www.crossac.com
Sleep clinics can be found internationally at the largest hospitals and universities, and there is a large body of
published work on the subject of snoring. It has been documented in clinical tests that much of sleep deprivation is
caused by snoring. Not only is the snorer disturbed, but those within close proximity of the noise are disturbed as
well. As the muscles relax during sleep, air flows in and out of the mouth causing the vibration of the tongue, soft
palate and uvula which produces the sound commonly referred to as snoring.
In 2002, the Company completed a double blind study at Northwestern Hospital's Sleep Center in Atlanta, GA,
under the direction of Dr. Samuel Mickelson of the Advanced Ear Nose and Throat P.C. The results of that study
concluded that SNORenz® is an effective product to reduce the noise associated with snoring.
Traditional snoring remedies include surgical procedures, mechanical devices and dental appliances. During
surgery, portions of the vibrating tissue are cut away by scalpel or laser in an attempt to remove the noise-making
tissues.
This type of procedure is painful, takes months to heal, and may not offer a long-term solution. Mechanical devices
primarily attempt to increase the volume of air or create positive air pressure using some type of breathing apparatus
connected to an air pump. This is not only uncomfortable; it also limits one's sleeping positions. Dental appliances
also attempt to increase the volume of air by expanding the opening of the mouth or by repositioning the lower jaw
and/or the tongue to decrease the vibration effect. Again, wearing one of these is not the most comfortable way to
sleep. The costs of these methods can be considerable and may not be covered by basic medical insurance
programs.
Snoring is a problem that affects over 60% of males and 40% of females. In the United States alone, it is
documented that there are over 94 million people who suffer with and from the effects of snoring. Snoring causes a
poor quality of sleep. The medical implications of snoring usually are not life threatening, except for a malady
called Sleep Apnea, which is not as yet curable. Therapy has been increasing in response to demand to solve the
side effects of snoring noise.
I remain excited and focused for our corporate future. I will follow up at the end of the month with a full report on
the success of the commercials!
Again I wish to thank all our loyal shareholders and I remind them to stay the course. As the quote stated don’t
worry about the daily fluctuations of your investment, rather hold true to your strategy and share in the success of
CXAC!
Please note that all future information will be released via PR's or shareholder letters. I am prohibited from speaking
to you on an individual basis.
Jorge Bravo
President / CEO